BRPI0410704A - uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete - Google Patents
uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabeteInfo
- Publication number
- BRPI0410704A BRPI0410704A BRPI0410704-7A BRPI0410704A BRPI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A
- Authority
- BR
- Brazil
- Prior art keywords
- tyrosine kinase
- diabetes
- kinase
- pdgf
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE INIBIDOR C-ABL-TIROSINA QUINASE, PDGF-R-TIROSINA QUINASE OU C-KIT-TIROSINA QUINASE NO TRATAMENTO DA DIABETE". A presente invenção refere-se ao uso de inibidor c-Abl- tirosina quinase, PDGF-R- tirosina quinase, ou c-kit-tirosina quinase, por exemplo 4(4-metilpiperazin-1-ilmetil)-N-¢4-metil-3-(4-piridin-3-il)-pirimidin-2ilamin o)fenil!-benzamida, ou um seu sal farmaceuticamente aceitável para a preparação de um medicamento para o tratamento da diabete, por exemplo, diabete do tipo I, diabete do tipo II.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312086A GB0312086D0 (en) | 2003-05-27 | 2003-05-27 | Organic compounds |
GB0402682A GB0402682D0 (en) | 2004-02-06 | 2004-02-06 | Organic compounds |
PCT/EP2004/005679 WO2004105763A2 (en) | 2003-05-27 | 2004-05-26 | Use of tyrosine kinase inhibitor to treat diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0410704A true BRPI0410704A (pt) | 2006-06-13 |
Family
ID=33492240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0410704-7A BRPI0410704A (pt) | 2003-05-27 | 2004-05-26 | uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete |
Country Status (21)
Country | Link |
---|---|
US (1) | US7875616B2 (pt) |
EP (1) | EP1631291B1 (pt) |
JP (1) | JP4776537B2 (pt) |
KR (1) | KR101102229B1 (pt) |
AT (1) | ATE439133T1 (pt) |
BR (1) | BRPI0410704A (pt) |
CA (1) | CA2526594C (pt) |
DE (1) | DE602004022540D1 (pt) |
DK (1) | DK1631291T3 (pt) |
ES (1) | ES2331800T3 (pt) |
HK (1) | HK1087638A1 (pt) |
IL (1) | IL171927A (pt) |
IS (1) | IS2712B (pt) |
MA (1) | MA27812A1 (pt) |
MX (1) | MXPA05012739A (pt) |
NO (1) | NO331715B1 (pt) |
NZ (1) | NZ543709A (pt) |
PL (1) | PL1631291T3 (pt) |
PT (1) | PT1631291E (pt) |
RU (1) | RU2365373C2 (pt) |
WO (1) | WO2004105763A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004013792D1 (de) * | 2003-08-15 | 2008-06-26 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
CN101484427A (zh) * | 2006-06-30 | 2009-07-15 | 协和发酵麒麟株式会社 | Abl激酶抑制剂 |
KR20140062485A (ko) * | 2011-09-15 | 2014-05-23 | 노파르티스 아게 | 중등도 간 손상 환자의 암 치료에 있어서 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온의 용도 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (pt) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
EP0773313B1 (de) * | 1995-10-11 | 2000-08-09 | ARTEVA TECHNOLOGIES S.à.r.l. | Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
HUP0301865A3 (en) | 2000-02-15 | 2005-12-28 | Teva Pharma | A method for synthesizing leflunomide |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
JP2004518669A (ja) | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | 4−アリール置換インドリノン |
AU2002334355A1 (en) * | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
AUPS243002A0 (en) | 2002-05-20 | 2002-06-13 | Baker Medical Research Institute | Therapeutic target and uses thereof |
DE10235227A1 (de) * | 2002-08-01 | 2004-02-19 | Johann Berger | Verfahren zur Herstellung eines gewebten Gurtbandes |
JP4588447B2 (ja) * | 2002-08-09 | 2010-12-01 | セラヴァンス, インコーポレーテッド | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
WO2004043408A2 (en) * | 2002-11-13 | 2004-05-27 | Genpath Pharmaceuticals, Incorporated | Gpc15: methods and compositions for treating cancer |
DE10255360A1 (de) * | 2002-11-27 | 2004-06-17 | Johann Berger | Verfahren zur Herstellung eines gewebten Gurtbandes |
-
2004
- 2004-05-26 DK DK04739375T patent/DK1631291T3/da active
- 2004-05-26 ES ES04739375T patent/ES2331800T3/es not_active Expired - Lifetime
- 2004-05-26 JP JP2006529925A patent/JP4776537B2/ja not_active Expired - Fee Related
- 2004-05-26 PL PL04739375T patent/PL1631291T3/pl unknown
- 2004-05-26 WO PCT/EP2004/005679 patent/WO2004105763A2/en active IP Right Grant
- 2004-05-26 DE DE602004022540T patent/DE602004022540D1/de not_active Expired - Lifetime
- 2004-05-26 PT PT04739375T patent/PT1631291E/pt unknown
- 2004-05-26 BR BRPI0410704-7A patent/BRPI0410704A/pt active Search and Examination
- 2004-05-26 US US10/556,984 patent/US7875616B2/en not_active Expired - Fee Related
- 2004-05-26 CA CA2526594A patent/CA2526594C/en not_active Expired - Fee Related
- 2004-05-26 MX MXPA05012739A patent/MXPA05012739A/es active IP Right Grant
- 2004-05-26 AT AT04739375T patent/ATE439133T1/de active
- 2004-05-26 KR KR1020057022515A patent/KR101102229B1/ko not_active IP Right Cessation
- 2004-05-26 RU RU2005140516/15A patent/RU2365373C2/ru not_active IP Right Cessation
- 2004-05-26 EP EP04739375A patent/EP1631291B1/en not_active Expired - Lifetime
- 2004-05-26 NZ NZ543709A patent/NZ543709A/xx not_active IP Right Cessation
-
2005
- 2005-11-14 IL IL171927A patent/IL171927A/en not_active IP Right Cessation
- 2005-11-22 IS IS8139A patent/IS2712B/is unknown
- 2005-11-24 MA MA28624A patent/MA27812A1/fr unknown
- 2005-12-23 NO NO20056188A patent/NO331715B1/no not_active IP Right Cessation
-
2006
- 2006-07-17 HK HK06107985.6A patent/HK1087638A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA05012739A (es) | 2006-05-17 |
HK1087638A1 (en) | 2006-10-20 |
US20070072932A1 (en) | 2007-03-29 |
KR101102229B1 (ko) | 2012-01-05 |
WO2004105763A3 (en) | 2005-06-02 |
ES2331800T3 (es) | 2010-01-15 |
MA27812A1 (fr) | 2006-03-01 |
WO2004105763A2 (en) | 2004-12-09 |
CA2526594A1 (en) | 2004-12-09 |
PL1631291T3 (pl) | 2010-04-30 |
AU2004243491A1 (en) | 2004-12-09 |
US7875616B2 (en) | 2011-01-25 |
ATE439133T1 (de) | 2009-08-15 |
JP2006528225A (ja) | 2006-12-14 |
DK1631291T3 (da) | 2009-11-02 |
IL171927A0 (en) | 2006-04-10 |
RU2005140516A (ru) | 2007-07-10 |
IS2712B (is) | 2011-01-15 |
IS8139A (is) | 2005-11-22 |
KR20060021865A (ko) | 2006-03-08 |
PT1631291E (pt) | 2009-10-28 |
RU2365373C2 (ru) | 2009-08-27 |
NO20056188L (no) | 2005-12-23 |
NZ543709A (en) | 2009-04-30 |
IL171927A (en) | 2011-10-31 |
EP1631291B1 (en) | 2009-08-12 |
EP1631291A2 (en) | 2006-03-08 |
DE602004022540D1 (de) | 2009-09-24 |
JP4776537B2 (ja) | 2011-09-21 |
NO331715B1 (no) | 2012-03-05 |
CA2526594C (en) | 2011-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
NO20055516L (no) | Kannabinoidreceptorligander og anvendelser derav | |
NO20052512L (no) | Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander | |
PT998473E (pt) | Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao | |
ATE468341T1 (de) | Thienopyrazole | |
EA200701181A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний | |
BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
EA200602154A1 (ru) | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 | |
ECSP077845A (es) | Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas | |
NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
NO20053876D0 (no) | Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav | |
BR0307286A (pt) | Tratamento de artrite reumatóide usando imatinib | |
RS51316B (sr) | Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli | |
TNSN05304A1 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
DE60226126D1 (de) | Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen | |
BRPI0517083A (pt) | uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase | |
WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
DE60305460D1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |